5.93
+0(+0.00%)
Currency In USD
| Previous Close | 5.93 |
| Open | 5.97 |
| Day High | 5.97 |
| Day Low | 5.88 |
| 52-Week High | 6.9 |
| 52-Week Low | 3.38 |
| Volume | 890,361 |
| Average Volume | 4.04M |
| Market Cap | 1.82B |
| PE | 59.3 |
| EPS | 0.1 |
| Moving Average 50 Days | 5.5 |
| Moving Average 200 Days | 4.78 |
| Change | 0 |
If you invested $1000 in MannKind Corporation (MNKD) 10 years ago, it would be worth $801.35 as of December 25, 2025 at a share price of $5.93. Whereas If you bought $1000 worth of MannKind Corporation (MNKD) shares 5 years ago, it would be worth $1,642.66 as of December 25, 2025 at a share price of $5.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MannKind Shares FUROSCIX® Business Updates
GlobeNewswire Inc.
Dec 23, 2025 1:05 PM GMT
FDA approves FUROSCIX® for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
GlobeNewswire Inc.
Dec 01, 2025 1:05 PM GMT
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and convenient option to address episodes of fluid buildup at
MannKind to Present at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
Nov 11, 2025 9:05 PM GMT
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial Officer, are scheduled to present